PREVENT 2027 E-01: Combining eicosapentaenoic acid and naproxen for colorectal cancer prevention
Forecast New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $700,000 to $1,500,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- Rachel Turk rachel.turk@nih.gov
- John Clifford john.clifford@nih.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
NIH plans to issue a new requirement with an estimated solicitation release date of December 1, 2026, for research to determine whether a modified stable form of eicosapentaenoic acid, alone or combined with naproxen, reduces colorectal cancer tumor burden and prolongs survival in a rat colon cancer model. The work begins with a pilot study comparing the stable form against a non-modified form previously shown effective in this model to establish relative chemopreventive activity and tolerability, followed by long-term studies to optimize doses and treatment schedules, determine durability of protection, and assess predictive biomarkers, with parallel studies in cultured patient-derived normal and colon tumor tissue providing human translational evidence.
The estimated award value range is $700,000 to $1,500,000, with an estimated award date of March 1, 2027. Points of contact are Rachel Turk (rachel.turk@nih.gov) and John Clifford (john.clifford@nih.gov), both at NIH.
Forecast text
The overall objective of this project is to determine whether a modified stable form of eicosapentanoic acid, (a polyunsaturated fatty acid that is commonly found in supplements taken for reducing cardiovascular risk), administered alone or in combination with the non-steroidal anti-inflammatory drug naproxen (trade name Aleve), in the diet, will reduce colorectal cancer tumor burden and prolong survival in a rat colon cancer model. A pilot study in the rat model will first compare the stable form of eicosapentanoic acid to a non-modified form that has previously been shown to be effective for suppressing/preventing colorectal cancer in this model. This experiment will establish relative chemopreventive activity and tolerability. Next, long-term studies will evaluate the stable form of eicosapentanoic acid alone and in combination with naproxen, to optimize the effective doses and treatment schedules, determine durability of protection against colorectal cancer development, and assess candidate biomarkers that are predictive of cancer preventive effectiveness. Parallel studies in patient-derived normal and colon tumor tissue that have been cultured in the laboratory, will provide complementary human translational evidence for colorectal cancer prevention and suppression.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast